February 4, 2026, marks the 27th World Cancer Day. For the period of 2025 to 2027, the Union for International Cancer Control (UICC) has established "United by Unique" as the central theme. This initiative aims to refocus cancer care on the individual, placing patients' unique needs and lived experiences at the core of medical and health decision-making. In alignment with this vision, the Chinese Anti-Cancer Association has designated "People-Centered, United Against Cancer" as China's official campaign theme for 2026.
Cancer remains a major global public health challenge. Data released in 2024 by the International Agency for Research on Cancer (IARC) shows that in 2022, there were approximately 20 million new cancer cases worldwide, resulting in about 9.7 million deaths. This underscores that the situation in prevention and treatment remains formidable.
As an innovation leader in China's oncology field, Alphamab Oncology is consistently guided by unmet clinical needs, committed to developing more effective and accessible breakthrough therapies with a favorable safety profile for patients worldwide, with the goals of extending survival and improving quality of life. Through sustained innovation, we aim to contribute to the global fight against cancer.
Guided by the model of "Technological Innovation and Platform Synergy", Alphamab Oncology has established differentiated portfolio of innovative products, covering cutting-edge candidates in antibody drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. Several candidates demonstrate "Best-in-Class" (BIC) or "First-in-Class" (FIC) potential. Notably: Envafolimab (KN035), received market approved in China in 2021, is the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment by avoiding intravenous infusion and can be administered in just 30 seconds. Anbenitamab (KN026), which submitted the first NDA in 2025, is the first HER2 bispecific antibody to demonstrate positive results in the second-line treatment of gastric cancer, holding the potential to reshape the treatment landscape for this indication. Building on this foundation, the company is actively expanding its innovative pipeline centered on targets like HER2 and PD-L1. Next-generation drug candidates, including bispecific ADC, dual-payload ADC, and subcutaneously administered bispecific ADC, are in development for various high-incidence cancers such as lung, gastric, breast, colorectal, and ovarian cancers.
We remain steadfast in our commitment to pioneering innovation. By collaborating with medical institutions, research teams, and all sectors of society, we translate "people-centered" philosophy into tangible clinical solutions. This ensures that more patients worldwide can benefit from individualized and precise therapies. Driven by innovation, we light the way forward for patients.
About Alphamab Oncology
Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
